Methods A retrospective analysis was conducted on all patients referred to BC Cancer who
(i) were diagnosed with pleural mesothelioma between January 2010 and December 2020 …

Simple Summary Immune-checkpoint inhibitors have only been studied in clinical trials for
second-line and now first-line malignant pleural mesothelioma. Sometimes, results found in …

Immune checkpoint inhibitors (ICI) have shown important but variable efficacy in
mesothelioma despite a lack of strong biological rationale. Initial trials assessed ICI …

Methods We designed a phase 1 safety run-in of the combination of anetumab ravtansine
(6.5 mg/kg iv q3weeks) and pembrolizumab (200 mg, IV q3weeks) followed by a phase 2 …

Background There is no recommended therapy for malignant pleural mesothelioma that has
progressed after first-line pemetrexed and platinum-based chemotherapy. Disease control …

8549 Background: Treatment options are limited for patients (pts) with MPM who experience
disease progression after first-line pemetrexed-based chemotherapy. This study was …

Malignant pleural mesothelioma (MPM) is a rare and aggressive neoplasm that arises from
the mesothelial lining of the pleura. MPM is the most common type of mesothelioma …

Ahmadzada et al. Biomarkers in mesothelioma who are candidates for surgery undergo
either extra-pleural pneumonectomy (EPP), which involves macroscopic removal of the …

Background Single-drug checkpoint inhibition has shown efficacy in patients with recurrent
malignant pleural mesothelioma. Here, we assessed the safety and efficacy of the …

Malignant pleural mesothelioma (MPM) is a rare cancer with increasing incidence and low
survival rates. Treatment advances in first-line therapy over the past two decades have been …